Neratinib is an oral irreversible inhibitor of EGFR/HER1, HER2, and HER4 tyrosine kinases that causes severe diarrhea and presents management issues for antidiarrheal treatment and/or prophylaxis to ensure the continuity of breast cancer treatment. This evidence concerns the gene ERBB4 and breast carcinoma.